β-Lactamase inhibitors

Drug Resistance Updates

Volumn 3, Issue 2, 2000, Pages 109-125

  Page, Malcolm G P ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Resistance; Lactamase; Lactamase inhibitor

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; BROBACTAM; CARBAPENEM; CLAVULANIC ACID; SULBACTAM; SULFAZECIN; SULFONE; TAZOBACTAM; THIENAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; DRUG MECHANISM; ENZYME INHIBITOR COMPLEX; ENZYME MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034176494     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2000.0137     Document Type: Article

References (110)

1. Bush K., Jacoby G. A., Medeiros A. A. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 39:1995;1211-1233.
2. Jones R. N., Kehrberg E. N., Erwin ME, et al. Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: real or perceived? Diagn Microbiol Infect Dis. 19:1994;203-215.
3. Bush K. β-Lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev. 1:1988;109-123.
4. Cartwright S. J., Waley S. G. β-Lactamase inhibitors. Med Res Rev. 3:1983;341-382.
5. Pratt R. F. β-Lactamase: inhibition. Page M. I., The chemistry of β-lactams. 1992;229-271 Blackie Academic & Professional, Glasgow.
6. Livermore D. M. Determinants of the activity of β-lactamase inhibitor combinations. J Antimicrob Chemother. 31A:1993;9-21.
7. Strynadka N. C. J., Adachi H., Jensen SE,et al. Molecular structure of the acyl-enzyme intermediate in β-lactam hydrolysis at 1.7 Å resolution. Nature. 359:1992;700-705.
8. Dideberg O., Charlier P., Wery J. P. The crystal structure of the β-lactamase of Streptomyces albus G at 3 Å resolution. Biochem J. 245:1987;911-913.
9. Herzberg O. Refined crystal structure of β-lactamase from Straphylococcus aureus PC1 at 2.0 Å resolution. J Mol Biol. 217:1991;701-719.
10. Knox J. R., Moews P. C. β-Lactamase of Bacillus licheniformis 749/C. Refinement at 2Å resolution and analysis of hydration. J Mol Biol. 220:1991;435-455.
11. Mourey L., Miyashita K., Swaren P., Bulychev A., Samama J-P., Mobashery S. Inhibition of NMC-A β-lactamase by a penicillanic acid derivative and the structural bases for the increase in substrate profile of this antibiotic resistance enzyme. J Am Chem Soc. 120:1998;9382-9383.
12. Kuzin A. P., Nukaga M., Hujer A. M., Bonomo R. A., Knox J. R. Structure of SHV-1 β-lactamase. Biochemistry. 38:1999;5720-5727.
13. Concha N. O., Rasmussen B. A., Bush K., Herzberg O. Crystal structure of the wide-spectrum binuclear zinc β-lactamase from Bacteroides fragilis. Structure. 4:1996;823-846.
14. Sutton B. J., Artymuik P. J., Cordero-Borboa A. E., Little C., Phillips D. C., Waley S. G. An X-ray crystallographic study of β-lactamase II from Bacillus cereus at 0.35 nm resolution. Biochem J. 248:1987;181-188.
15. Carfi A., Pares S., Duée E. The 3D-structure of a zinc metallo-β-lactamase from Bacillus subtilis reveals a new type of protein fold. EMBO J. 14:1995;4919-4921.
16. Oefner C., D'Arcy A., Daly J. J. Refined crystal structure of β-lactamase from Citrobacter freundii indicates a mechanism for β-lactam hydrolysis. Nature. 343:1990;284-288.
17. Lobkovsky E., Moews P. C., Liu H., Zhao H., Frère J. M., Knox J. R. Evolution of an enzyme activity: crystallographic structure at 2-Å resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc Natl Acad Sci USA. 90:1993;11257-11261.
18. Usher K. C., Blaszczak L. C., Weston G. S., Shoichet B. K., Remington S. J. Three-dimensional structure of AmpC β-lactamase from Escherichia coli bound to a transition state analogue: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry. 37:1998;16082-16092.
19. Paetzel, M. Danel, F. de Castro, L. Page, M. G. P. Strynadka, N. C. J. The first crystal structure of a broad spectrum class D β-lactamase, OXA-10, at 2.0 A resolution (in press).
20. Brown A. G., Butterworth D., Cole M. Naturally occurring β-lactamase inhibitors with antibacterial activity. J Antibiot. 29:1976;668-669.
21. Doran J. C., Leskiv B. K., Aippersbach S., Jensen S. E. Isolation and characterization of a β-lactamase inhibitory protein from Streptomyces claviguligerus and cloning and analysis of the corresponding gene. J Bacteriol. 172:1990;4904-4918.
22. Strynadka N. C. J., Jensen S. E., Johns K. Structural and kinetic characterization of a β-lactamase inhibitory protein. Nature. 368:1994;657-660.
23. Cartwright S. J., Coulson A. F. W. A semi-synthetic penicillinase inactivator. Nature. 278:1979;360-361.
24. Charnas R. L., Fisher J., Knowles J. R. Chemical studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid. Biochemistry. 17:1978;2185-2189.
25. Rizwi I., Tan A. K., Fink A. L., Virden R. Clavulanate inactivation of Staphylococcus aureusβ-lactamase. Biochem J. 258:1989;205-209.
26. Chen C. C. H., Herzberg O. Inhibition of β-lactamase by clavulanate. Trapped intermediates in cryocrystallographic studies. J Mol Biol. 224:1992;1103-1113.
27. Matagne A., Ghuysen M. F., Frère J. M. Interactions between active site serine β-lactamases and mechanism-based inactivators: kinetic study and an overview. Biochem J. 295:1993;705-711.
28. Fisher J., Charnas R. L., Knowles J. R. Kinetic studies on the inactivation of Escherichia coli RTEM β-lactamase by clavulanic acid. Biochemistry. 17:1978;2180-2184.
29. Brown R. P. A., Aplin R. T., Schofield C. J. Inhibition of TEM-2 β-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry. Biochemistry. 35:1996;12421-12432.
30. Imitiaz U., Billings E. M., Knox J. R. Inactivation of class A β-lactamases by clavulanic acid: the role of arginine 244 in a proposed non-concerned sequence of events. J Am Chem Soc. 115:1993;4435-4442.
31. Matagne A., Frère J. M. Contribution of mutant analysis to the understanding of enzyme catalysis: the case of class A β-lactamases. Biochem Biophys Acta. 1246:1995;109-127.
32. Oliphant A.R., Struhl K. An efficient method for generating protein with altered enzymatic properties: application to β-lactamase. Proc Natl Acad Sci USA. 86:1989;9094-9098.
33. Bonomo R. A., Currie-McCumber C., Shlaes D. M. OHIO-1 β-lactamase resistant to mechanism-based inactivators. FEMS Microbiol Lett. 92:1992;79-82.
34. Bonomo R. A., Dawes C. G., Knox J. R., Shlaes D. M. Complementary roles of mutations at positions 69 and 242 in a class A β-lactamase. Biochim Biophys Acta. 1247:1995;113-120.
35. Brun T., Péduzzi J., Canica M. Characterization and amino acid sequence, IRT-4, a novel TEM-type enzyme with a decreased susceptibility to β-lactamase inhibitors. FEMS Microbiol Lett. 120:1994;111-117.
36. Bonomo R. A., Dawes C. G., Knox J. R., Shlaes D. M. β-Lactamase mutations far from the active site influence inhibitor binding. Biochim Biophys Acta. 1247:1995;121-125.
37. Swarén P., Golemi D., Cabantous S., Bulychev A., Maveyraud L., Mobashery S. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 β-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid. Biochemistry. 38:1999;9570-9576.
38. English A. R., Retsema J. A., Girard A. E., Lynch J. E., Barth W. E. CP-45.899, a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactams: initial bacteriological characterization. Antimicrob Agents Chemother. 14:1978;414-419.
39. Fisher J., Charnas R. L., Bradley S. M., Knowles J. R. Inactivation of the RTEM β-lactamase from Escherichia coli. Interaction of penam sulfones with the enzyme. Biochemistry. 20:1981;2726-2731.
40. Brenner D. G., Knowles J. R. Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6α- and 6β-monodeuterio and of 6,6-dideuterio derivatives with RTEM β-lactamase from Escherichia coli. Biochemistry. 20:1981;3680-3687.
41. Kemal C., Knowles J. R. Penicillanic acid sulfone: interaction with RTEM β-lactamase from Escherichia coli at different pH values. Biochemistry. 20:1981;3688-3695.
42. Imitiaz U., Billings E. M., Knox J. R., Mobashery S. A structure-based analysis of the inhibition of class A β-lactamases by sulbactam. Biochemistry. 33:1994;5728-5738.
43. Aronoff S. C., Jacobs M. R., Joehning S., Yamabe S. Comparative activities of the β-lactamase inhibitors YTR830, sodium clavulanate and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agents Chemother. 26:1984;580-582.
44. Richter H. G. F., Angehrn P., Hubschwerlen C. Design, synthesis, and evaluation of 2β-alkenyl penam sulfone acids as inhibitors of β-lactamases. J Med Chem. 39:1996;3712-3722.
45. Bush K., Macalintal C., Rasmussen B. A., Lee V. J., Yang Y. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob Agents Chemother. 37:1993;851-858.
46. Buynak J. D., Borate H. B., Lamb G. W. Synthesis of 6-vinylidenepenams. J Org Chem. 58:1993;1325-1335.
47. Buynak J. D., Geng B., Bachmann B., Hua L. The synthesis and lactamase inhibitory activity of 6-(carboxymethylene)penicillins and 7-(carboxymethylene) cephalosporins. Biorg Med Chem Lett. 5:1995;1513-1518.
48. Eby P., Cummings M. D., Phillips O. β-Lactamase inhibitors: synthesis and in vitro evaluation of 6-[(1-substituted-1,2,3-triazol-4-y1)methylene]-penicillanic acid sulfones. Heterocycles. 42:1996;653-668.
49. Heinze-Krauss I., Angehrn P., Charnas R. L. Structure-based design of β-lactamase inhibitors. 1. Synthesis and evaluation of bridged monobactams. J Med Chem. 41:1998;3961-3971.
50. Kahan J. S., Kahan F. M., Goegelman R. Thienamycin. A new β-lactam antibiotic I. Discovery, taxonomy. Isolation and physical properties. J Antibiot. 32:1979;1-12.
51. Charnas R. L., Knowles J. R. Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of enzyme with derivatives of olivanic acid. Biochemistry. 20:1981;2732-2737.
52. 1 pyrroline tautomerization of carbapenem antibiotics by the highly conserved Arg244 of class A β-lactamases during the course of turnover. J Am Chem Soc. 114:1992;1505-1506.
53. Maveyraud L., Mourey L., Kotra L. P. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A β-lactamases from antibiotic-resistant bacteria. J Am Chem Soc. 120:1998;9748-9752.
54. Dubus A., Normark S., Kania M. Role of asparagine 152 in catalysis of β-lactam hydrolysis by Escherichia coli AmpC β-lactamase studied by site-directed mutagenesis. Biochemistry. 34:1995;7757-7764.
55. Naas T., Vandel L., Sougakoff W., Livermore D. M., Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A beta-lactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother. 38:1994;1262-1270.
56. Nordmann P., Mariotte S., Naas T., Labia R., Nicolas M. H. Biochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli. Antimicrob Agents Chemother. 37:1993;939-946.
57. Donald, H. M. Amyes, S. G. B. Young, H. K. Biochemical characterization of ARI-1, a novel class D β-lactamase responsible for imipenem resistance inAcinetobacter baumannii. Abstr. 1462, 39th Intersci Conf Antimicrob Agents Chemother, 1999 Am Soc Microbiol, Washington D.C.
58. Butterworth D., Cole M. D., Manscomb G., Rawlinson G. N. Olivanic acids, a family of β-lactam antibiotics with β-lactamase inhibitory properties produced byStreptomyces species. J. Antibiot. 32:1978;287-294.
59. Ito, T. Ezaki, N. Ohba, K. A novel β-lactamase inhibitor SF-2103 A produced by a Streptomyces. J Antibiot, 182, 533, 535.
60. Tsuji N., Nagashoima K., Hobayashi M., Terui Y., Matsumoto K., Kondo E. The structures of pluracidomycins, new carbapenem antibiotics. J Antibiot. 35:1982;536-540.
61. Easton C. J., Knowles J. R. Inhibition of the RTEM β-lactamase from Escherichia coli. Interaction of the enzyme with derivatives of olivanic acid. Biochemistry. 21:1982;2857-2862.
62. 2, new carbapenem antibiotics. IV. Inhibitory activity against β-lactamases. J Antibiot. 34:1981;212-217.
63. Kobayashi F., Saino Y., Koshi T. Antimicrobial and β-lactamase inhibitory activities of carpetimycins A and B, new carbapenem antibiotics. Antimicrob Agents Chemother. 21:1982;536-544.
64. Tsuji N., Kondo E., Mayama M. Asparenomycin A, a new carbapenem antibiotic. J Antibiot. 34:1981;909-911.
65. Tsuji N., Nagashima K., Kobayashi M. Asparenomycins A, B, and C, new carbapenem antibiotics III. Structures. J Antibiot. 35:1982;24-31.
66. Murakami K., Doi M., Yoshida T. Asparenomycins A, B and C, new carbapenem antibiotics. V. Inhibition of β-lactamases. J Antibiot. 35:1982;39-45.
67. Arisawa M., Then R. L. 6-Acetylmethylenepenicillanic acid (Ro 15-1903), a potent β-lactamase inhibitor. I. Inhibition of chromosomally and R-factor mediated β-lactamases. J Antibiot. 35:1982;1578-1583.
68. Coleman K., Griffin D. R. J., Page J. W. J., Upshon P. A. In vitro evaluation of BRL 42715, a novel β-lactamase inhibitor. Antimicrob Agents Chemother. 33:1989;1580-1587.
69. Broom N. J. P., Farmer T. F., Osborne N. F., Tyler J. W. Studies on the mechanism of action of (5 R)-(Z)-6-(1-methyl-1,2,3-triazol-4-ylmethylene)penem-3-carboxylic acid (BRL 42715), a potent inhibitor of bacterial β-lactamase. J Chem Soc Chem Commun. 1992;1663-1664.
70. Sykes R. B., Cimanusti C. M., Bonner D. P. Monocyclic β-lactam antibiotics produced by bacteria. Nature. 291:1981;489-491.
71. Imada A., Kitano K., Kintaka K., Asai M. Sulfazecin and isosulfazecin, novel β-lactam antibiotics of bacterial origin. Nature. 289:1981;590-591.
72. Matsuda K., Sanada M., Nakawaga S., Inoue M., Mitashashi S. Preferential hydrolysis of cis configuration compounds at the 3,4 position of monobactams by β-lactamase fromMorganella morgani. Antimicrob Agents Chemother. 35:1991;458-461.
73. Hubschwerlen C., Angehrn P., Gubernator K., Page M. G. P., Specklin J. L. Structure-based design of β-lactamase inhibitors. 2. Synthesis and evaluation of bridged sulfactams and oxamazins. J Med Chem. 41:1998;3972-3975.
74. Böhringer, M. Hubschwerlen, C. Pflieger, P. Specklin, J. L. PCT Int. Appl. 1995, EP-A-0671401.
75. Pflieger P., Angehrn P., Böhringer M. Bridged Carbacephems. Bentley P. H., O'Hanlon P. J., Anti-infectives, recent advances in chemistry and structure-activity relationships. 1997;101-115 The Royal Soc Chem, Cambridge.
76. Faraci W. S., Pratt R. F. Mechanism of inhibition of the PCI β-lactamase of Staphylococcus aureus by cephalosporins: importance of the 3′-leaving group. Biochemistry. 24:1985;903-910.
77. Pratt R. F., Loosemore M. J. 6β-Bromopenicillanic acid, a potent β-lactamase inhibitor. Proc Natl Acad Sci USA. 75:1978;4145-4149.
78. Knott-Huniziker V., Orlek B. S., Sammes P. G., Waley S. G. 6β-Bromopenicillanic acid inactivates β-lactamase I. Biochem J. 177:1979;365-367.
79. Von Daehne A. 6β-Halopenicillanic acids, a group of β-lactamase inhibitors. J Antibiot. 33:1980;451-452.
80. Pratt R. F., Cohen S. A. Inactivation of Bacillus cereusβ-lactamase I by 6β-bromopenicillanic acid: mechanism. Biochemistry. 19:1980;3996-4003.
81. Moorman A. R., Abeles R. H. A new class of serine protease inactivators based on isatoic anhydride. J Am Chem Soc. 104:1982;6785-6786.
82. Page M. G. P. The kinetics of non-stoichiometric bursts of β-lactam hydrolysis catalysed by class C β-lactamases. Biochem J. 1993;295-304.
83. Wharton C. W., Page M. G. P., Chittock R. S., Regan T. E., Ward S. Infrared spectroscopy of enzyme reaction intermediates, Laser Chem. 19:1999;209-222.
84. Shinogi M., Agha B. J., Tsuji K., Digenis G. A. Assessment of antiprotease activity of some carbamate derivatives. J Pharmaceutical Sci. 74:1985;482-485.
85. Citri N., Samuni A., Zyk N. Acquisition of substrate-specific parameters during the catalytic reaction of penicillinase. Proc Natl Acad Sci USA. 73:1976;1048-1052.
86. Lindquist RN Terry C. Inhibition of subtilisin by boronic acids, potential analogues of tetrahedral reaction intermediates. Arch Biochem Biophys. 160:1974;135-144.
87. Kiener P. A., Waley S. G. Reversible inhibitors of penicillinases. Biochem J. 134:1978;386-392.
88. Beesley T., Gascoyne N., Knott-Hunziker V. The inhibition of class C β-lactamases by boronic acids. Biochem J. 209:1983;229-233.
89. 11B NMR spectroscopy. J Chem Soc Chem Commun. 1991;573-574.
90. Strynadka N. C. J., Martin R., Jensen S. E., Gold M., Jones J. B. Structure based design of a potent transition state analogue for TEM-1 β-lactamase. Nature Struct Biol. 3:1996;688-695.
91. Crompton I. E., Cuthbert B. K., Lowe G., Waley S. G. β-Lactamase inhibitors; the inhibition of serine β-lactamases by specific boronic acids. J Biochem. 251:1988;453-459.
92. Weston G. S., Blázquez J., Baquero F., Shoichet B. K. Structure-based enhancement of boronic acid-based inhibitors of AmpC β-lactamase. J Med Chem. 41:1998;4577-4586.
93. Pratt R. F. Inhibition of a class C β-lactamase by a specific phosphonate monoester. Science. 246:1989;917-919.
94. Chen C. C. H., Rahil J., Pratt R. F., Herzberg O. Structure of a phosphonate-inhibited β-lactamase. An analog of the tetrahedral transition state/intermediate of β-lactam hydrolysis. J Mol Biol. 234:1993;165-178.
95. Maveyraud L., Pratt R. F., Samama J. P. Crystal structure of an acylation transition-state analog of the TEM-1 β-lactamase. Mechanistic implications for class A β-lactamases. Biochemistry. 37:1998;2622-2628.
96. Lobkovsky E., Billings E. M., Moews P. C., Rahil J., Pratt R. F., Knox J. R. Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a beta-lactamase transition state analog. Biochemistry. 33:1994;6762-6772.
97. Strynadka N. C.J., Jensen S. E., Alzari P. M., James M. N.G. A potent new mode of b-lactamase inhibition rehibition revealed by the 1.7 Å X-ray crystallographic structure of the TEM-1 - BLIP complex. Nature Struct Biol. 3:1996;290-297.
98. Petrosino J., Rudgers G., Gilbert H., Palzkill T. Contributions of aspartate 49 and phenylalanine 142 residues of a tight binding inhibitory protein of β-lactamases. J Biol Chem. 274:1999;2394-2400.
99. Rudgers G. W., Palzkill T. Identification of residues in β-lactamase critical for binding β-lactamase inhibitory protein. J Biol Chem. 274:1999;6963-6971.
100. Huang W., Zhang Z., Palkill T. Design of potent β-lactamase inhibitors by phage display of β-lactamase inhibitory protein. J Biol Chem. 2000.
101. Yang D., Roll D. M., Wildley M. J. Inhibition of metallo-β-lactamases by LL-10G568a and LL-10G568b, Abstr. C56, 34th Intersci Conf on Antimicrob Agents Chemother. Am Soc Microbiol, Washington, D.C., 1994.
102. Bateson, J. H. Gilpin, M. L. Payne, D. J. PCT Int. Appl. 1997, WO9710225-A1.
103. Walter M. W., Felici A., Galleni M. Trifluoromethyl alcohol and ketone inhibitors of metallo-β-lactamases. Bioorg Med Chem Lett. 6:1996;2455-2458.
104. Walter M. W., Adlington R. M., Baldwin J. E., Schofield C. J. Synthesis of metallo-β-lactamase inhibitors. Tetrahedron. 53:1997;7275-7290.
105. Concha N., Janson C. A., Rowling P. Crystal structure of the IMP-1 metallo-β-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent broad-spectrum inhibitor. Biochemistry. 2000.
106. Scrofani S. D. B., Chung J., Huntley J. J. A., Benkovic S. J., Wright P. E., Dyson H. J. NMR characterization of the metallo-β-lactamase from Bacteroides fragilis and its interaction with a tight binding inhibitor: role of an active-site loop. Biochemistry. 38:1999;14507-14514.
107. Payne D. J., Bateson J. H., Gasson B. C. Inhibition of metallo-β-lactamases by a series of mercaptoacetic acid thiol derivatives. Antimicrob Agents Chemother. 41:1997;135-140.
108. Fitzgerald P. M. D., Wu J. K., Toney J. H. Unanticipated inhibition of the metallo-β-lactamase from Bacteroides fragilis by 4-morpholinosulfonic acid (MES): a crystallographic study at 1.85 Å resolution. Biochemistry. 37:1998;6791-6800.
109. Toney J. H., Fitzgerald P. M. D., Groversharma N., Olson S. H., May W. J. Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-β-lactamase. Chem Biol. 5:1998;185-196.
110. Li X. Z., Zhang L., Srikumur R., Poole K. β-Lactamase inhibitors are substrates for the multidrug efflux pumps of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 42:1998;399-403.